1. Home
  2. SUPN vs HSAI Comparison

SUPN vs HSAI Comparison

Compare SUPN & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • HSAI
  • Stock Information
  • Founded
  • SUPN 2005
  • HSAI 2014
  • Country
  • SUPN United States
  • HSAI China
  • Employees
  • SUPN N/A
  • HSAI N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • HSAI
  • Sector
  • SUPN Health Care
  • HSAI
  • Exchange
  • SUPN Nasdaq
  • HSAI Nasdaq
  • Market Cap
  • SUPN 2.6B
  • HSAI 2.8B
  • IPO Year
  • SUPN 2012
  • HSAI 2023
  • Fundamental
  • Price
  • SUPN $54.61
  • HSAI $23.95
  • Analyst Decision
  • SUPN Strong Buy
  • HSAI Strong Buy
  • Analyst Count
  • SUPN 3
  • HSAI 4
  • Target Price
  • SUPN $62.67
  • HSAI $31.58
  • AVG Volume (30 Days)
  • SUPN 725.2K
  • HSAI 2.6M
  • Earning Date
  • SUPN 11-04-2025
  • HSAI 11-11-2025
  • Dividend Yield
  • SUPN N/A
  • HSAI N/A
  • EPS Growth
  • SUPN 1411.53
  • HSAI N/A
  • EPS
  • SUPN 1.14
  • HSAI 0.11
  • Revenue
  • SUPN $665,125,000.00
  • HSAI $347,701,639.00
  • Revenue This Year
  • SUPN $7.31
  • HSAI $61.81
  • Revenue Next Year
  • SUPN $21.87
  • HSAI $45.58
  • P/E Ratio
  • SUPN $46.18
  • HSAI $212.32
  • Revenue Growth
  • SUPN 5.55
  • HSAI 36.51
  • 52 Week Low
  • SUPN $29.16
  • HSAI $4.02
  • 52 Week High
  • SUPN $53.28
  • HSAI $30.85
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 78.22
  • HSAI 46.34
  • Support Level
  • SUPN $49.95
  • HSAI $21.64
  • Resistance Level
  • SUPN $52.15
  • HSAI $23.27
  • Average True Range (ATR)
  • SUPN 1.36
  • HSAI 1.21
  • MACD
  • SUPN 0.30
  • HSAI -0.12
  • Stochastic Oscillator
  • SUPN 97.61
  • HSAI 43.13

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About HSAI Hesai Group each ADS represents one Class B ordinary share

Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.

Share on Social Networks: